

1 **Predictors for participation in DNA self-sampling of childhood cancer survivors in**

2 **Switzerland**

3 Nicolas Waespe, MD,^{1,2,3} Sven Strebel, MSc Pharm,^{1,2,4} Denis Marino MSc,² Veneranda

4 Mattiello, MD,^{2,5} Fanny Muet, MSc,² Tiago Nava, MD,^{2,5} Christina Schindera, MD,^{1,6}

5 Fabien N. Belle, PhD,^{1,7} Luzius Mader, PhD,¹ Adrian Spoerri, PhD, MPH,⁸ Claudia E.

6 Kuehni, MD, MSc,^{1,9,*} Marc Ansari, MD.^{2,5,*}

7

8 *) Shared equally contributing senior authors.

9 ¹ Childhood Cancer Research Group, Institute of Social and Preventive Medicine,

10 University of Bern, Bern, Switzerland;

11 ² CANSEARCH research platform for paediatric oncology and haematology, Faculty of

12 Medicine, Department of Pediatrics, Gynecology and Obstetrics, of the University of

13 Geneva, Geneva, Switzerland;

14 ³ Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern,

15 Bern, Switzerland;

16 ⁴ Graduate School for Health Sciences (GHS), University of Bern, Bern, Switzerland;

17 ⁵ Division of Pediatric Oncology and Hematology, Department of Women, Children,

18 and Adolescents, University Hospital of Geneva, Geneva, Switzerland;

19 ⁶ Pediatric Oncology/Hematology, University Children's Hospital Basel, University of

20 Basel, Basel, Switzerland;

21 ⁷ Center for Primary Care and Public Health (Unisanté), Institute of Social and

22 Preventive Medicine (IUMSP), University of Lausanne, Lausanne, Switzerland;

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 ⁸ SwissRDL - Medical Registries and Data Linkage, Institute of Social and Preventive

24 Medicine, University of Bern, Bern, Switzerland;

25 ⁹ Division of Pediatric Oncology and Hematology, Department of Pediatrics,

26 University Hospital of Bern, Bern, Switzerland.

27

28 **Corresponding author:** Prof. Dr. med. Marc Ansari, MD; Division of Pediatric

29 Oncology and Hematology, Department of Women, Children, and Adolescents,

30 University Hospital of Geneva, Rue Willy-Donzé 6; Bureau 5-507; 1211 Genève,

31 Switzerland; T: +41 22 372 47 31; F : +41 22 382 31 00

32 E-mail : marc.ansari@hcuge.ch

33

34 Word count Abstract: (200/ 200, unstructured)

35 Word count Main Text: (1987/ max. 2000 words)

36 Number of Tables and Figures: (2/ 2 max)

37 Number of Supporting Information files: (1/open)

38 References: (18/ 20)

39 **Short running title:** Participation in DNA self-sampling

40

41 **Key words (max 3-10):** childhood cancer, cancer survivors, DNA, cohort study, drug

42 side effects, second primary neoplasm, genetic predisposition, registry, genetic testing,

43 genetic polymorphism.

44 **ABSTRACT**

45 Research on germline genetic variants relies on a sufficient number of eligible
46 participants which is difficult to achieve for rare diseases such as childhood cancer.

47 With self-collection kits using saliva or buccal swabs, participants can contribute
48 genetic samples conveniently from their home. We identified determinants of
49 participation in DNA self-collection in this cross-sectional study.

50 We invited 928 childhood cancer survivors in Switzerland with a median age of 26.5
51 years (interquartile range 18.8-36.5), of which 463 (50%) participated. Foreign
52 nationality (odds ratio [OR] 0.5, 95%-confidence interval [CI] 0.4-0.7), survivors aged
53 30-39 years at study versus other age groups (OR 0.5, CI 0.4-0.8), and those with a
54 known cancer predisposition syndrome (OR 0.5, CI 0.3-1.0) participated less. Survivors
55 with a second primary neoplasm (OR 1.9, CI 1.0-3.8) or those living in a French or
56 Italian speaking region (OR 1.3, 1.0-1.8) tended to participate more.

57 We showed that half of survivors participate in germline DNA self-sampling relying
58 completely on mailing of sample kits. Foreign nationality, age 30-39 years, and cancer
59 predisposition syndromes were associated with less participation. More targeted
60 recruitment strategies may be advocated for these subgroups. To increase participation
61 in DNA self-sampling, understanding and perceptions of survivors need to be better
62 understood.

63

64

65

66 **MAIN MANUSCRIPT**

67 **1. INTRODUCTION**

68 Cancer survivorship and associated health complications have become increasingly
69 important with improved childhood cancer survival.[1] Chronic conditions like cardiac,
70 pulmonary, auditory, endocrine, reproductive, and neurocognitive complications, and
71 second primary neoplasms (SPNs) are gaining importance in research and clinical care.[2]
72 By age 50 years, childhood cancer survivors have twice as many severe chronic health
73 conditions compared to controls.[3] Mortality in survivors is more than 10-times higher
74 than in the general population.[4] While many demographic, clinical, and treatment-
75 related risk factors are known, the contribution of genetic variation in the development of
76 health complications is still poorly understood. Therefore, research group collect
77 germline DNA samples systematically to enable research on genetic risk factors.[5–7]

78 Self-sampling of germline DNA by participants has increased the reach of sample
79 collection because many do not attend regular medical care. Since the 1990's buccal
80 swabs are used. In the 2010's saliva collection kits became widely available which are
81 easy to use and yield DNA of good quality and sufficient quantity.[8] Saliva collection
82 kits do not need time-sensitive processing or cooling like blood, but can be collected,
83 transported, and stored in ambient conditions for years. Collection of saliva samples by
84 participants themselves is feasible and effective.[5] Self-collection may, however, be
85 affected by participation bias. Ness et al. identified female sex, white race/ethnicity,
86 college graduation, never smoking, accessing the healthcare system in the past 2 years,
87 and having a second malignant neoplasm as predictors for participating in saliva sample
88 self-collection.[5] Outside of the US, predictors for participation in childhood cancer
89 survivors have not been studied. They might differ based on the perception of the

90 healthcare system and acceptance of genetic research. We assessed the response rate and
91 investigated predictors for participation in saliva self-sampling in Switzerland as part of
92 the national Germline DNA Biobanking for Childhood Cancer and Blood Disorders
93 (BISKIDS) project.

94

95

96 **2. METHODS**

97 **2.1. Study design**

98 We used contact information from the Swiss Childhood Cancer Registry (SCCR) at the
99 Institute of Social and Preventive Medicine, University of Bern, Switzerland to invite
100 childhood cancer survivors for germline DNA self-collection in this cross-sectional study
101 design. Addresses were collected from hospitals involved in primary and follow-up care
102 and updated through the Swiss national postal service.

103 We obtained data on patient characteristics from the SCCR. In September 2019,
104 participants received self-sampling kits by postal mail at their home and were asked to
105 send them to the germline DNA Biobank Switzerland for Childhood Cancer and Blood
106 Disorders (BISKIDS), which is part of the Paediatric Biobank for Research in
107 Haematology and Oncology (BaHOP) Geneva, Switzerland. BaHOP was awarded a
108 VITA label from the Swiss Biobanking Platform (SBP;
109 www.biobanksqan.ch/#/biobanks/3919; bbmri-
110 eric:ID:CH_HopitauxUniversitairesGeneve:collection:CH_BaHOP). All participants
111 received an informed consent form together with the saliva kit. The Geneva Cantonal
112 Commission for Research Ethics has approved the BaHOP biobank (approval PB_2017-

113 00533) and the associated “Genetic Risks for Childhood Cancer Complications
114 Switzerland (GECCOS)” study, which will utilize the samples (approval 2020-01723).

115

116

117 **2.2. Study population**

118 Eligible for invitation to our study were participants who were: (i) registered in SCCR;
119 (ii) Swiss residents; (iii) treated in one of nine paediatric hospitals caring for children with
120 cancers; (iv) diagnosed with a neoplasm according to the International Classification of
121 Childhood Cancers, 3rd edition (ICCC-3), or Langerhans cell histiocytosis before age 21
122 years from 1976 to 2017; (v) exposed to lung toxic (chest radiotherapy) or ototoxic
123 treatment (brain radiotherapy with ≥ 30 Gray or platinum chemotherapy); and (vi)
124 survivors of 2 years or more since childhood cancer diagnosis as of July 2019. We
125 excluded participants who: (I) had declined participation in research projects; (II) had
126 died; or (III) did not have a valid address in Switzerland.

127

128 **2.3. Outcome definition and clinical characteristics**

129 Our main outcome was participation in the germline DNA sample collection, defined as
130 returning the DNA sample and the signed consent form. Non-participation was defined
131 as active decline or non-response until December 2020 (end of follow-up). Clinical
132 information was extracted from the SCCR. We recorded the age at first neoplasm in 5-
133 year groups, calendar year at first neoplasm diagnosis and age at survey in 10-year groups,
134 and the ICCC-3 main category [9] of the first neoplasm. Chemotherapy, radiotherapy,

135 and haematopoietic stem cell transplantation were classified as “yes” if given during the
136 first neoplasm treatment. We classified cancer predisposition syndrome and second
137 primary neoplasms as previously described.[10]

138

139

140

141 **2.4. Sample collection**

142 Survivors received by postal mail a letter with information on the planned DNA sample
143 collection, and a form with which they could opt and a prepaid return envelope. Those
144 who did not opt out received 3 weeks later a parcel including (i) detailed information on
145 the biobanking project and an informed consent form to sign, (ii) one Oragene DNA OG-
146 500 saliva sampling kit (manufactured by DNA Genotek, Ottawa, Ontario, Canada) with
147 material for return by regular mail (liquid-tight bio-specimen bag, bubble wrap), (iii)
148 information on saliva sample collection and shipment provided by the manufacturer
149 ([www.dnagenotek.com/row/products/collection-human/oragene-dna/500-series/OG-](http://www.dnagenotek.com/row/products/collection-human/oragene-dna/500-series/OG-500.html)
150 [500.html](http://www.dnagenotek.com/row/products/collection-human/oragene-dna/500-series/OG-500.html)), (iv) a graphical abstract of the workflow of saliva collection and return of
151 samples and consent forms, and (v) prepaid return envelopes for return of the consent
152 form and the saliva sample. We sent two letters as reminders to those who did not return
153 the sample, one after 6 weeks and another one after 8 weeks.

154 We offered participants the opportunity to receive additional information through (i) a
155 project specific e-mail address, and (ii) a dedicated telephone hotline. Both were operated
156 by the study coordinator, a trained specialist in paediatric haematology and oncology with
157 experience in cancer genetics, or biobank staff in case of absence.

158

159

160 2.5. Statistical analysis

161 We compared demographic, neoplasm, treatment, and follow-up information of
162 participants with non-participants. Univariable logistic regression and multivariable
163 logistic regression models were fitted to identify determinants of participation. Covariates
164 were kept in the multivariable logistic regression model using backward selection. We
165 removed covariates with $p \geq 0.2$. We additionally adjusted for sex and age at first primary
166 neoplasm diagnosis in the model. We used the software Stata version 15 (Stata
167 Corporation, Austin, Texas) for analyses. Statistical uncertainty of estimates was
168 expressed as 95%-confidence intervals.

169

170

171 3. RESULTS

172 3.1. Characteristics of cohort

173 We traced and contacted 928 of 1,215 eligible childhood cancer survivors (**Figure 1**).
174 Of those we contacted, 463 (50%) returned a germline DNA sample. Median age at
175 diagnosis was 8.7 years (interquartile range [IQR] 3-13) and at invitation 26.5 years
176 (IQR 19-37; **Table 1**). The most common diagnoses were central nervous system
177 tumours (28%) and lymphomas (21%) which reflected our selection process of inviting
178 former childhood cancer patients with pulmotoxic and ototoxic treatments. Most
179 patients had been treated with chemotherapy, about two thirds with radiotherapy, and a

180 minority with haematopoietic stem cell transplantation. Relapse had been confirmed in
181 21% of survivors, a second primary neoplasm in 4% and a cancer predisposition
182 syndrome (CPS) in 5%. Survivors were predominantly from the German (n=633, 68%)
183 language region and the remaining from the French (n=262, 28%) and Italian (33, 4%)
184 language region, which roughly reflects the language distribution in Switzerland.
185

Table 1: Characteristics of 928 Swiss childhood cancer survivors invited to home collection of germline DNA, stratified by participation status.

Characteristic	Participation			Univariable logistic regression		Multivariable logistic regression	
	Total (n, %) ^a	Yes (n, %) ^a	No (n, %) ^a	OR (95%-CI)	p-value	OR (95%-CI)	p-value
Sex							
Female	426 (46)	209 (45)	217 (47)	Ref.		Ref.	
Male	502 (54)	254 (55)	248 (53)	1.06 (0.82 - 1.38)	0.64	1.09 (0.83-1.42)	0.53
Nationality							
Swiss	710 (76)	377 (81)	333 (72)	Ref.		Ref.	
Foreign	218 (24)	86 (19)	132 (28)	0.58 (0.42-0.78)	<0.001	0.53 (0.38-0.73)	<0.001
Correspondence language							
German	633 (68)	308 (67)	325 (70)	Ref.		Ref.	
French and Italian	295 (32)	155 (34)	140 (30)	1.17 (0.89-1.54)	0.27	1.31 (0.98-1.75)	0.07
Age at first neoplasm diagnosis							
Median (IQR, years)	8.7 (3.0-13.4)	8.7 (3.0-13.4)	8.6 (3.6-13.3)				
0-4 years	311 (34)	166 (36)	145 (31)	1.14 (0.83 – 1.57)	0.35	1.08 (0.75-1.56)	0.4
5-9 years	212 (23)	97 (21)	115 (25)	0.84 (0.59 - 1.20)		0.79 (0.54-1.14)	
10-14 years	287 (31)	144 (31)	143 (31)	Ref.		Ref.	
15-20 years	118 (13)	56 (12)	62 (13)	0.90 (0.58 - 1.38)		0.95 (0.61-1.48)	
Year of diagnosis							
1976-1985	110 (12)	54 (12)	56 (12)	0.84 (0.55 - 1.30)	0.02	‡	
1986-1995	193 (21)	78 (17)	115 (25)	0.59 (0.41 - 0.85)		‡	
1996-2005	312 (34)	164 (35)	148 (32)	0.97 (0.71 - 1.33)		‡	
2006-2016	313 (34)	167 (36)	146 (31)	Ref.		‡	

Diagnostic group of first primary neoplasm (ICCC-3)					
Leukaemias, myeloproliferative and myelodysplastic diseases	35 (4)	14 (3)	21 (5)	0.77 (0.37-1.58)	0.38
Lymphomas	190 (21)	95 (21)	95 (20)	1.15 (0.79-1.68)	
CNS tumours and miscellaneous intracranial and intraspinal neoplasms	256 (28)	119 (26)	137 (30)	Ref.	
Neuroblastoma and other peripheral nervous cell tumours	78 (8)	45 (10)	33 (7)	1.57 (0.94-2.62)	
Retinoblastoma	44 (5)	18 (4)	26 (6)	0.8 (0.42-1.53)	
Renal tumours	33 (4)	20 (4)	13 (3)	1.77 (0.85-3.71)	
Hepatic tumours	24 (3)	15 (3)	9 (2)	1.92 (0.81-4.54)	
Malignant bone tumours	100 (11)	56 (12)	44 (10)	1.47 (0.92-2.33)	
Soft tissue and other extraosseous sarcomas	94 (10)	48 (10)	46 (10)	1.2 (0.75-1.93)	
Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	64 (7)	29 (6)	35 (8)	0.95 (0.55-1.65)	
Other malignant epithelial neoplasms and malignant melanomas	6 (1)	2 (<1)	4 (1)	0.58 (0.1-3.2)	
Langerhans cell histiocytosis	4 (<1)	2 (<1)	2 (<1)	1.15 (0.16-8.3)	
Chemotherapy					
No	61 (7)	25 (5)	36 (8)	Ref.	
Yes	867 (93)	438 (95)	429 (92)	1.47 (0.87-2.49)	0.15
- With platinum agents	491 (54)	259 (56)	232 (50)	1.27 (0.98-1.64)	0.07
Radiotherapy					
No	319 (34)	160 (35)	159 (34)	Ref.	
Yes	609 (66)	303 (65)	306 (66)	0.98 (0.75-1.29)	0.91
- With head radiotherapy (≥30 Gy)	343 (37)	166 (36)	177 (38)	0.91 (0.70-1.19)	0.49
- With chest radiotherapy	328 (35)	156 (34)	172 (37)	0.87 (0.66-1.33)	0.29

Haematopoietic stem cell transplantation

No	864 (93)	428 (92)	436 (94)	Ref.			
Yes	64 (7)	35 (8)	29 (6)	1.23 (0.74-2.05)	0.43		

Relapse of first neoplasm

No	738 (80)	368 (80)	370 (80)	Ref.			
Yes	190 (21)	95 (21)	95 (20)	1.01 (0.73-1.38)	0.97		

Cancer predisposition syndrome

No	879 (95)	442 (96)	437 (94)	Ref.		Ref.	
Yes	49 (5)	21 (5)	28 (6)	0.74 (0.42-1.33)	0.31	0.54 (0.29-1.0)	0.05

Second primary neoplasm

No	889 (96)	438 (95)	451 (97)	Ref.		Ref.	
Yes	39 (4)	25 (5)	14 (3)	1.84 (0.94-3.58)	0.07	1.92 (0.97-3.82)	0.06

Age at study invitation

Median (IQR, years)	26.5 (18.8-36.5)	25.1 (18.3-35.2)	27.7 (19.5-37.3)				
<10 years	50 (5)	23 (5)	27 (6)	0.72 (0.4-1.32)	0.005	0.75 (0.39-1.43)	0.002
10-19 years	215 (23)	121 (26)	94 (20)	1.09 (0.77-1.56)		1.17 (0.81-1.70)	
20-29 years	296 (32)	160 (35)	136 (29)	Ref.		Ref.	
30-39 years	198 (21)	78 (17)	120 (26)	0.55 (0.38-0.8)		0.54 (0.38-0.79)	
40 or more years	169 (18)	81 (18)	88 (19)	0.78 (0.54-1.14)		0.72 (0.48-1.07)	

187 **Legend:** ‡, omitted from multivariable regression model for collinearity with age at study invitation; CNS, central nervous system; ICC3, international
188 classification of childhood cancer, edition 3; IQR, interquartile range; n, number

189 3.2. Recruitment and impact of reminders

190 We invited 928 survivors for home saliva collection. After the first information letter,
191 64 (7%) actively declined participation through an opt-out reply form. The remaining
192 864 survivors received a saliva sampling kit and an informed consent form. Seventy-
193 seven of those actively refused participation (8%) and 324 eligible survivors did not
194 answer (35%). Within 6 weeks after the send out of the sampling kit, 291 (63%)
195 participated (**Supplementary Figure 1**). The first reminder letter led to 117 additional
196 participants (25%) and the second reminder to an additional 55 participants (12%). On
197 the consent form, 383 (83%) indicated that they wanted to be informed about potential
198 incidental findings and 394 (85%) agreed that their samples could be used after death.

199

200 3.3. Covariates associated with participation

201 Foreign nationality (odds ratio [OR] 0.5, 95%-confidence interval [CI] 0.4-0.7) and age
202 at study were associated with non-participation. Survivors aged 30-39 years participated
203 least (OR 0.5, CI 0.4-0.8), those 10-29 years tended to participate best, and those <10
204 years and >40 years in between. Those with a cancer predisposition syndrome tended to
205 participate less (OR 0.5, CI 0.3-1.0), while survivors with a diagnosis of a second
206 primary neoplasm (OR 1.9, CI 1.0-3.8) and those who spoke French or Italian (OR 1.3,
207 CI 1.0-1.8) tended to participate more. There were no differences in sex, age at first
208 primary neoplasm diagnosis, diagnostic groups, treatments, and relapse of first primary
209 neoplasm between participants and non-participants.

210

211

212 4. DISCUSSION

213 This study described participation of Swiss childhood cancer survivors in home saliva
214 collection for germline DNA extraction. We confirmed previous findings of about 50%
215 participation in home DNA self-collection. Foreign nationality was a strong predictor
216 for non-participation. Survivors with known CPSs and aged 30-39 years were also less
217 likely to participate. In contrast, survivors with second primary neoplasms were more
218 likely to participate. Most participating survivors wanted to be informed about
219 incidental findings that might be relevant to their health and most agreed to their
220 samples being available for research after their death.

221

222 The overall response rate of 50% was comparable to other DNA sample self-collections
223 from home. Ness et al. reported 54% participation on 10,356 eligible adult childhood
224 cancer survivors[5] and Dykema found 54% participation in 8,081 adults in the
225 Wisconsin Longitudinal Study.[11] Nishita et al. offered an incentive of 25US\$ for
226 returning a saliva sample which led to 59% participation of 967 adults in a smoking
227 cessation trial, which was only slightly higher than in studies without incentive.[12]
228 Lower participation was found in genetic assessment of preterm birth where 23% of 708
229 mothers participated.[13] Higher participation rates were achieved in an active clinical
230 setting with patient-caregiver interaction where 97% of 155 adults from the US
231 participated.[14]

232

233 Foreign nationality was strongly associated with non-participation in concordance with
234 a previous study from our group on response to questionnaire studies.[15] This could be

235 related to language issues affecting understanding or reluctance to participate in
236 research due to lower confidence in research. Foreign nationality is also linked to lower
237 socioeconomic status, which was a predictor for lower participation in research.[16]
238 Easy to understand information material, maybe in more languages, and information by
239 phone might counteract these differences in participation. Our findings on language
240 difference were in contrast to a large Swiss survey on willingness to participate in
241 personalized health research,[16] and our group's previous publication on participation
242 in a questionnaire study,[15] where German speaking people were more likely to
243 participate. The former was sent from the previously treating institutions and the latter
244 from a German speaking research institution. In our study, the invitation was sent off
245 from Geneva hospital, situated in the French speaking language region, which might
246 have improved acceptance of the study of the CCS living in this language region.
247 Survivors with known CPSs were less willing to participate in our study. Reasons could
248 be the impression of futility as participants were already investigated, fear of further
249 findings, or bad experiences with genetic workup. Survivors with second primary
250 neoplasms tended to participate more, potentially because they were seeking
251 explanations for their multiple neoplasms. Lower participation in older survivors might
252 be reflective of being more distanced to the previous disease or in a busy phase of their
253 lives (caring for children and being active at work).

254

255 A limitation of our study was the lack of information on reasons for non-participation.
256 We further did not send additional sampling kits with reminders which might have
257 prevented survivors from participating who had discarded their kit already. Strengths
258 were the availability of clinical information including CPSs. Our results of the study are

259 likely representative for childhood cancer survivors in other countries with similar trust
260 in healthcare institutions and responsible (genetic) research.

261

262 Our study illustrates that home saliva collection through a process completely relying
263 on mail is feasible and yields a response rate of about 50%. Specific survivor groups
264 (foreign nationality, age 30-39 years, and patients with cancer predisposition
265 syndromes) were less likely to participate which needs to be taken into account when
266 studies are planned.

267

268

269 **Abbreviations table:**

270	BaHOP	Biobank for Hematology and Oncology in Pediatrics
271	BISKIDS	Germline DNA Biobank Switzerland for Childhood Cancer and
272		Blood Disorders
273	CCS	Childhood cancer survivor
274	CNS	Central nervous system
275	CPS	Cancer predisposition syndrome
276	DNA	Deoxyribonucleic acid
277	GECCOS	Genetic risks for childhood cancer complications Switzerland
278	HSCT	Hematopoietic stem cell transplantation
279	ICCC-3	International Classification of Childhood Cancer, third edition
280	ISPM	Institute of Social and Preventive Medicine
281	SCCR	Swiss Childhood Cancer Registry
282	SPN	Second primary neoplasm

283

284 **Acknowledgements**

285 We thank all childhood cancer patients, survivors, and families for participating in our
286 study. We thank the study team of the Childhood Cancer Research Group, Institute of
287 Social and Preventive Medicine, University of Bern, and SCCSS (Tomas Slama,
288 Fabienne Luzi, Maria Otth, Selma Riedo), the data managers of the Swiss pediatric
289 oncology clinics (Claudia Althaus, Nadine Assbichler, Pamela Balestra, Heike
290 Baumeler, Nadine Beusch, Sarah Blanc, Pierluigi Brazzola, Susann Drerup, Janine
291 Garibay, Franziska Hochreutener, Monika Imbach, Friedgard Julmy, Eléna Lemmel,
292 Heike Markiewicz, Annette Reinberg, Renate Siegenthaler, Astrid Schiltknecht, Beate
293 Schwenke, and Verena Stahel) and the data managers and administrative staff of the
294 SCCR (Meltem Altun, Erika Brantschen, Katharina Flandera, Elisabeth Kiraly, Verena
295 Pfeiffer, Julia Ruppel, Ursina Roder, and Nadine Lötscher). We thank the study team of
296 the CANSEARCH research platform in paediatric oncology and haematology of the
297 University of Geneva (Khalil Ben Hassine, Simona Jurkovic Mlakar, Vid Mlakar,
298 Shannon Robin), and the Onco-Hematology Unit of the HUG (Frederic Baleyrier,
299 Fanette Bernard, André von Bueren, Fabienne Gumy-Pause, Nelly Hafner-Bénichou,
300 Rodolfo Lo Piccolo).

301

302

303 **Competing interests**

304 The authors declare that they have no competing interests

305

306 **STROBE Checklist:** Supplementary File.

307 **Funding**

308 This study is supported by the CANSEARCH Foundation for BISKIDS, the host
309 biobank BaHOP, the research study GECCOS, and salary support to Nicolas Waespe
310 and Sven Strebel. Further funding comes from the Swiss National Science Foundation
311 (31BL30_185396), and Swiss Cancer Research (KFS-4722-02-2019, KLS/KFS-4825-
312 01-2019).

313 The funding bodies have no role in the design of the study and collection, analysis, and
314 interpretation of data and in writing this manuscript.

315

316 **Ethics approval and consent to participate**

317 The Geneva Cantonal Commission for Research Ethics has approved the BaHOP
318 biobank (approval PB_2017-00533) and the Genetic Risks for Childhood Cancer
319 Complications Switzerland (GECCOS) study, which will utilize the samples (approval
320 2020-01723).

321

322 **Trial registration**

323 Clinicaltrials.gov: NCT04702321

324

325 **Consent for publication**

326 All participants signed informed consents themselves or through their guardians.

327

328 **Availability of data and materials**

329 Datasets are available from the corresponding author on reasonable request for specific
330 projects.

331

332

333 **Authors' contributions**

334 NW: Conceptualization, Design, Methodology, Formal analysis, Data curation, Project
335 administration, Writing - all stages, Visualization.

336 SSt: Project administration, Writing – Reviewing and Editing

337 FB, LM: Writing – Reviewing and Editing

338 TN: Conceptualization, Design, Methodology, Writing – Reviewing and Editing

339 DM, VM: Conceptualization, Data curation, Project administration, Writing –
340 Reviewing and Editing

341 FM: Data curation, Project administration, Visualisation, Writing – Reviewing and
342 Editing

343 AS: Conceptualization, Design, Methodology, Writing - Reviewing and Editing.

344 CEK, MA: Supervision, Conceptualization, Design, Methodology, Writing - Reviewing
345 and Editing.

346

347 All authors have approved the submitted version.

348 **References**

- 349 1 Bhatia S, Armenian SH, Armstrong GT, van Dulmen-den Broeder E, Hawkins MM,
350 Kremer LCM, Kuehni CE, Olsen JH, Robison LL, Hudson MM. Collaborative Research in
351 Childhood Cancer Survivorship: The Current Landscape. *JCO* 2015;**33**:3055–64.
- 352 2 Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM,
353 Armstrong GT, Nottage KA, Jones KE, Sklar CA, Srivastava DK, Robison LL. Clinical
354 Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer. *JAMA*
355 2013;**309**:2371–81.
- 356 3 Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, Chemaitilly W, Ehrhardt MJ, Bass
357 J, Bishop MW, Shelton K, Lu L, Huang S, Li Z, Caron E, Lanctot J, Howell C, Folsø T,
358 Joshi V, Green DM, Mulrooney DA, Armstrong GT, Krull KR, Brinkman TM, Khan RB,
359 Srivastava DK, Hudson MM, Yasui Y, Robison LL. The cumulative burden of surviving
360 childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). *The*
361 *Lancet* 2017;**390**:2569–82.
- 362 4 Schindler M, Spycher BD, Ammann RA, Ansari M, Michel G, Kuehni CE, for the Swiss
363 Paediatric Oncology Group (SPOG). Cause-specific long-term mortality in survivors of
364 childhood cancer in Switzerland: A population-based study. *Int J Cancer* 2016;**139**:322–33.
- 365 5 Ness KK, Li C, Mitby PA, Radloff GA, Mertens AC, Davies SM, Hammond S, Armstrong
366 GT, Robison LL. Characteristics of responders to a request for a buccal cell specimen
367 among survivors of childhood cancer and their siblings. *Pediatr Blood Cancer*
368 2010;**55**:165–70.
- 369 6 Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen A,
370 Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink MM, van Dulmen-den Broeder
371 E, Baust K, Bautz A, Beck JD, Berger C, Binder H, Borgmann-Staudt A, Broer L, Cario H,
372 Casagrande L, Clemens E, Deuster D, de Vries A, Dirksen U, Falck Winther J, Fosså S,
373 Font-Gonzalez A, Grandage V, Haupt R, Hecker-Nolting S, Hjorth L, Kaiser M, Kenborg
374 L, Kepak T, Kepáková K, Knudsen LE, Krawczuk-Rybak M, Kruseova J, Kuehni CE,
375 Kunstreich M, Kuonen R, Lackner H, Leiper A, Loeffen EAH, Luks A, Modan-Moses D,
376 Mulder R, Parfitt R, Paul NW, Ranft A, Ruud E, Schilling R, Spix C, Stefanowicz J, Strauß
377 G, Uitterlinden AG, van den Berg M, van der Kooi A-L, van Dijk M, van Leeuwen F, Zolk
378 O, Zöller D, Kaatsch P, PanCareLIFE consortium. PanCareLIFE: The scientific basis for a
379 European project to improve long-term care regarding fertility, ototoxicity and health-
380 related quality of life after cancer occurring among children and adolescents. *Eur J Cancer*
381 2018;**103**:227–37.
- 382 7 Wang Z, Wilson CL, Easton J, Thrasher A, Mulder H, Liu Q, Hedges DJ, Wang S, Rusch
383 MC, Edmonson MN, Levy S, Lanctot JQ, Caron E, Shelton K, Currie K, Lear M, Patel A,
384 Rosencrance C, Shao Y, Vadodaria B, Yergeau D, Sapkota Y, Brooke RJ, Moon W,
385 Rampersaud E, Ma X, Chang T-C, Rice SV, Pepper C, Zhou X, Chen X, Chen W, Jones A,
386 Boone B, Ehrhardt MJ, Krasin MJ, Howell RM, Phillips NS, Lewis C, Srivastava D, Pui C-
387 H, Kesslerwan CA, Wu G, Nichols KE, Downing JR, Hudson MM, Yasui Y, Robison LL,
388 Zhang J. Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of
389 Childhood Cancer. *JCO* 2018;:JCO.2018.77.8589.


- 390 8 Rogers NL, Cole SA, Lan H-C, Crossa A, Demerath EW. New saliva DNA collection
391 method compared to buccal cell collection techniques for epidemiological studies.
392 *American Journal of Human Biology* 2007;**19**:319–26.
- 393 9 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of
394 Childhood Cancer, third edition. *Cancer* 2005;**103**:1457–67.
- 395 10 Waespe N, Belle FN, Redmond S, Schindera C, Spycher BD, Rössler J, Ansari M, Kuehni
396 CE, Ansari M, Beck-Popovic M, Bourquin J-P, Brazzola P, Greiner J, Rössler J,
397 Scheinemann K, Schilling F, Weid N von der. Cancer predisposition syndromes as a risk
398 factor for early second primary neoplasms after childhood cancer – A national cohort study.
399 *European Journal of Cancer* 2021;**145**:71–80.
- 400 11 Dykema J, DiLoreto K, Croes KD, Garbarski D, Beach J. Factors Associated with
401 Participation in the Collection of Saliva Samples by Mail in a Survey of Older Adults.
402 *Public Opinion Quarterly* 2017;**81**:57–85.
- 403 12 Nishita DM, Jack LM, McElroy M, McClure JB, Richards J, Swan GE, Bergen AW.
404 Clinical trial participant characteristics and saliva and DNA metrics. *BMC Medical*
405 *Research Methodology* 2009;**9**:71.
- 406 13 Keag OE, Murphy L, Bradley A, Deakin N, Whyte S, Norman JE, Stock SJ. Postal
407 recruitment for genetic studies of preterm birth: A feasibility study. *Wellcome Open Res*
408 2020;**5**:26.
- 409 14 McElfish PA, Narcisse M-R, Long CR, Ayers BL, Hawley NL, Aitaoto N, Riklon S, Su LJ,
410 Ima SZ, Wilmoth RO, Schulz TK, Kadlubar S. Leveraging community-based participatory
411 research capacity to recruit Pacific Islanders into a genetics study. *J Community Genet*
412 2017;**8**:283–91.
- 413 15 Rueegg CS, Gianinazzi ME, Michel G, Zwahlen M, von der Weid NX, Kuehni CE. No
414 evidence of response bias in a population-based childhood cancer survivor questionnaire
415 survey — Results from the Swiss Childhood Cancer Survivor Study. *PLoS One* 2017;**12**.
416 doi:10.1371/journal.pone.0176442
- 417 16 Brall C, Berlin C, Zwahlen M, Ormond KE, Egger M, Vayena E. Public willingness to
418 participate in personalized health research and biobanking: A large-scale Swiss survey.
419 *PLoS ONE* 2021;**16**:e0249141.

420

421

422

1 **Figure 1.** Flowchart of the response to invitation to the BISKIDS home collection of
2 germline DNA in 928 patients.



29 **Legend:** ICCC-3, international classification of childhood cancer, edition 3; n, number